GlobeNewswire Inc | Oct 21, 2020 04:30PM EDT

October 21, 2020

SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report third quarter 2020 financial results on Thursday, November 5, 2020 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.

Conference Call Information Date: Thursday, November 5, 2020Time: 4:30 p.m. ETDial-in +1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International)numbers:Confirmation 7362327code:Live webcast: Retrophin.com in the ?Events & Presentations? section of the ?Investors? page

A replay of the call will be available from 7:30 p.m. ET, November 5, 2020 to 7:30 p.m. ET, November 12, 2020. The replay number is +1 (855) 859-2056 (U.S.) or +1 (404) 537-3406 (International), confirmation code 7362327.

AboutRetrophin

Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare disease. The Companys approach centers on its pipeline featuring sparsentan, a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), rare disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including partnerships with leaders in patient advocacy and government research to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, conditions with no approved treatment options. Retrophins R&D efforts are supported by revenues from the Companys commercial products Chenodal, Cholbam, Thiola and Thiola EC.

Retrophin.com

Contact:Chris Cline, CFASenior Vice President, Investor Relations & Corporate Communications888-969-7879IR@retrophin.com